Ulcerative Proctitis
📧 Sign up to get email alerts when something new happens for Ulcerative Proctitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-06Clinical Trial Results: Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories [Phase 3]
Phase 3 trial results for hydrocortisone acetate suppositories in ulcerative proctitis have been completed with results posted.
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: The Prevalence of Chlamydia Trachomatis and Neisseria Gonorrhoeae in Patients Suspected of Hemorrhagic Proctosigmoiditis
An observational clinical trial sponsored by the University of Aarhus aims to determine how prevalent Chlamydia trachomatis and Neisseria go…
-
CLINICAL_TRIALS trial_result · 2025-07-30Clinical Trial Update: Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories [Phase 3]
Phase 3 trial assessing safety and efficacy of hydrocortisone acetate suppositories for ulcerative proctitis has completed.
-
FDA approval · 2023-10-24FDA Approved: CANASA — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for CANASA (mesalamine) submitted by Allergan, Inc.
-
FDA approval · 2022-11-16FDA Approved: CANASA — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for CANASA (mesalamine) by Allergan, Inc., resulting in updated labeling for this product.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-11-01FDA Approved: CANASA — Supplemental Application (Allergan, Inc.)
FDA approves a supplemental application for CANASA (mesalamine) by Allergan, Inc.
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis [Phase 3]
Phase 3 trial of MAX-002 suppository for mild to moderate ulcerative proctitis was terminated; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-08-14Clinical Trial Update: Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis [Phase 3]
Phase 3 trial assessing efficacy and safety of budesonide foam in active mild to moderate ulcerative proctitis or proctosigmoiditis complete…
-
CLINICAL_TRIALS trial_result · 2019-08-14Clinical Trial Update: Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis [Phase 3]
Phase 3 trial assessing the efficacy and safety of budesonide foam in active mild to moderate ulcerative proctitis or proctosigmoiditis; tri…
-
CLINICAL_TRIALS trial_result · 2019-05-07Clinical Trial Update: Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis [Phase 2]
Phase 2 trial comparing budesonide, mesalazine, and budesonide/mesalazine suppository therapy in acute ulcerative proctitis has completed.
-
CLINICAL_TRIALS trial_result · 2016-12-15Clinical Trial Update: Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis [Phase 4]
Phase 4 trial evaluating rectal tacrolimus for resistant ulcerative proctitis (a form of ulcerative colitis) has completed.
-
FDA approval · 2013-05-03FDA Approved: CANASA — Supplemental Application (Allergan, Inc.)
The FDA approved Allergan's supplemental application for CANASA (mesalamine), indicating a regulatory action to update or expand the product…
-
FDA approval · 2013-02-06FDA Approved: CANASA — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for CANASA (mesalamine) by Allergan, Inc. The approval indicates that changes submitted in the suppl…
-
FDA approval · 2008-05-23FDA Approved: CANASA — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for CANASA (mesalamine) from Allergan, Inc., marking an additional approval for this product.
-
FDA approval · 2006-06-08FDA Approved: CANASA — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for CANASA (mesalamine) submitted by Allergan, Inc.